预测性报告显示,新药IMM-1-104的胰腺癌治疗结果前景光明。 Immuneering reports promising pancreatic cancer treatment results with new drug IMM-1-104.

免疫公司报告了IMM- 1-104在胰腺癌的第二阶段试验的有希望的结果,显示与改性gemcitabine/ nab- paclitaxel结合时,总体应答率为43%和疾病控制率为86%. Immuneering Corporation reported promising results from its Phase 2a trial for IMM-1-104 in pancreatic cancer, showing a 43% overall response rate and 86% disease control rate when combined with modified gemcitabine/nab-paclitaxel. 使用经修改的FOLFIRINOX时,该药物还展示了所有可评价患者中的目标损伤缩水。 The drug also demonstrated target lesion shrinkage in all evaluable patients when used with modified FOLFIRINOX. 仅二线治疗中IMM-1-104的初始数据表明,在减少损害方面有67%的部分反应。 Initial data for IMM-1-104 alone in second-line treatment showed a 67% partial response in lesion reduction. 该公司计划在2025年开始新的组合试验,包括黑瘤中BRAF抑制剂和黑瘤和非小细胞肺癌中的免疫检查站抑制剂。 The company plans to start new combination trials in 2025, including with BRAF inhibitors in melanoma and immune checkpoint inhibitors in melanoma and non-small cell lung cancer.